Clinical efficacy of glucocorticoid on primary endocardial fibroelastosis in children

• Published in: Jie fang jun yi xue za zhi Vol. 43; no. 4; p. 341
• Main Authors: Zhi-xin, LI, Jia-rong ZHONG, WANG, Dan, LIU, Hu, ZHANG, Jing
• Format: Journal Article
• Language: Chinese
• Published: Beijing People's Military Medical Press 01.01.2018
• ISSN: 0577-7402
• DOI: 10.11855/j.issn.0577-7402.2018.04.14

Objective To study the clinical efficacy of glucocorticoid in treatment of primary endocardial fibroelastosis (EFE) in children. Methods Fifty-eight primary EFE cases admitted in the Children's Hospital of Chongqing Medical University from Jan. 2006 to Dec. 2013 were treated and followed-up for more than 3 years. Based on whether the application of glucocorticoid and the length of time of glucocorticoid therapy, cases were divided into three groups: no glucocorticoid group (n=15), glucocorticoid 0.5-1 year group (n=17) and glucocorticoid 1-2 year group (n=26). The following indicators were followed up and observed: the cardiac function indexes before and after treatment [Modified ROSS score, left ventricular ejection fraction (LVEF), left ventricular fractional shortening (LVFS)], cardiac size [cardiothoracic ratio (C/T)] and the proportion of death. The efficacy and safety of glucocorticoid were studied. Results No statistically significant difference of modified ROSS scores, LVEF, LVFS and C/T existed among